GV

GV Management Company, LLC, established in 2009 as the venture capital arm of Alphabet Inc., specializes in investments across various stages, including seed, early, and late-stage funding. Based in Mountain View, California, with additional offices in Boston, New York, Seattle, Cambridge, and London, GV focuses on sectors such as life sciences, healthcare, artificial intelligence, robotics, transportation, cybersecurity, and agriculture. The firm has invested in over 300 companies, aiming to drive innovation and improve lives. GV seeks to make investments of up to $50 million, while offering early-stage startups funding of up to $250,000, typically taking minority stakes in these companies. Through its extensive network, GV provides startups with unique access to technology and talent, enhancing their potential for success.

Karim Faris

General Partner

Crystal Huang

Partner

Rick Klau

Partner

David Krane

Managing Partner

Daniel Lynch

Executive Venture Partner

David P. Schenkein

General Partner

KJ Sidberry

Principal

Krishna Yeshwant

General Partner

Sangeen Zeb

General Partner

Past deals in Growth Stage

AMP Robotics

Series C in 2023
AMP Robotics Corporation specializes in designing and manufacturing robotic systems for material recovery facilities and recycling operations, focusing on automating the identification, sorting, and processing of complex waste streams. The company's flagship product, AMP Cortex, utilizes advanced robotics and computer vision technology to efficiently pick and sort recyclable materials, significantly lowering sorting costs. Additionally, AMP Neuron, a software solution, captures and analyzes material data to identify features in a manner similar to human perception. By leveraging artificial intelligence and machine learning, AMP Robotics enhances recycling processes for various waste types, including municipal solid waste and e-waste. The modular design of its systems allows for easy integration into existing infrastructure, minimizing disruption and capital investment. Founded in 2014 and headquartered in Louisville, Colorado, AMP Robotics has formed strategic partnerships to further its mission of improving recycling rates and economic recovery of recyclables.

Cerevance

Series B in 2023
Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle the early onset of various neurological diseases.

Flatfile

Series B in 2022
Flatfile Inc. offers a platform designed to streamline the data onboarding process for businesses by allowing developers to validate, map, and import data from various web applications. Founded in 2018 and based in Denver, Colorado, the company's key products include Portal, an import button that integrates seamlessly into software applications through a JavaScript snippet, and Concierge, which provides secure workspaces for collaboration on data ingestion challenges. Flatfile's platform supports multiple file formats, including CSV, XLS, and TSV, and features a JavaScript configurator that enables users to define target models for data validation. This automation helps organizations manage and structure imported data effectively, reducing the time spent on data cleaning and allowing teams to focus on utilizing their data for decision-making.

Sardine

Series B in 2022
FinTech, RegTech, Fraud Operating System

Merlin Labs

Series B in 2022
Merlin Labs is building an autonomous infrastructure for the sky above us, enabling goods, and eventually people, to fly without pilots.

Medallion

Series C in 2022
Medalion helps hospitals to empower their practice for market expansion while maintaining compliance.

Courier

Series B in 2022
Courier provides an API designed for developers to enhance user notification delivery by intelligently routing messages across various existing channels, such as email and messaging platforms. The API takes into account factors like user online status and previous engagement levels to determine the most effective communication method. Over the years, Courier has evolved significantly, continuously adapting to technological advancements to better serve its customers while maintaining stability in its management and operational approach. The company emphasizes the importance of customer success, fostering long-term relationships with its largest clients and collaborating closely to prepare for future developments in the industry.

Sesame

Series B in 2022
Sesame, Inc., operating as SesameCare, is a New York-based company that provides a platform for booking medical appointments and consultations. Founded in 2018, the company aims to simplify healthcare by connecting patients directly with doctors, offering transparent pricing and clear descriptions of medical services. SesameCare primarily serves uninsured individuals or those who prefer to pay for their healthcare services upfront. By addressing the complexities and hidden costs often associated with traditional healthcare, Sesame seeks to make quality medical care more accessible and affordable for a broader range of patients.

Nava

Series B in 2022
Nava is a New York-based company that specializes in health insurance brokerage services aimed at delivering high-quality, affordable healthcare solutions to employers and their employees. The firm provides a range of healthcare tools, year-round employee advocacy, and continuous measurement to assess and recommend healthcare plans. By focusing on these aspects, Nava helps clients manage their employee benefits effectively while reducing overall plan costs. This approach allows businesses to offer the necessary benefits to their workforce, ensuring both accessibility and affordability in healthcare coverage.

FarmWise

Series B in 2022
FarmWise Labs, Inc. specializes in the development and manufacturing of robotic machinery aimed at improving agricultural practices. The company focuses on creating vegetable weeders that offer effective weeding and thinning solutions, while also monitoring the growth of herbicides. Founded in 2016 and located in San Francisco, California, FarmWise employs mechanical engineering to enhance farming efficiency and streamline operations, ultimately supporting increased food production. The company was previously known as DeepLook, Inc.

Gametime

Venture Round in 2022
Gametime United, Inc. develops a mobile application to book tickets. The company’s application enables users to buy and sell tickets for NBA, NHL, MLB, MLS, NCAA, and NFL teams. It offers its application for iOS and Android platforms through App Store and the Google Play Store. The company was founded in 2012 and is based in San Francisco, California.

Mirvie

Series B in 2022
Mirvie is a biotech company that creates precise, actionable, and non-invasive tests for maternal-fetal health. The company delivers insights to moms and families to make pregnancy safe. It was founded in 2018 by Maneesh Jain and is headquartered in South San Francisco, California, United States.

Invetx

Series B in 2022
Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in developing protein-based therapeutics for animal health care. The company focuses on creating biopharmaceutical solutions that apply human biotechnology advancements to veterinary medicine. Invetx aims to build a premier innovation platform for veterinary therapeutics, collaborating with leading biotechnology firms, investors, and industry experts. Its team, which includes veterinary scientists and clinicians, is dedicated to discovering and developing a diverse portfolio of therapies and technologies. The company's vision is to enhance health outcomes for both pets and farm animals by leveraging biopharma technologies in the global animal health industry.

Aspen Neuroscience

Series B in 2022
Aspen Neuroscience, Inc. is a private biotechnology company based in San Diego, California, focused on developing innovative therapies for neurological conditions, particularly Parkinson's disease. Established in 2018, the company utilizes induced pluripotent stem cells to create patient-specific restorative cell therapies. Its product pipeline includes ANPD001, an autologous neuron replacement therapy designed for sporadic Parkinson's disease, and ANPD002, a gene-edited version aimed at familial forms of the disease. Aspen Neuroscience combines genomic approaches with stem cell biology to advance its mission of modifying the course of Parkinson's disease through these novel therapeutic strategies.

OMass Therapeutics

Series B in 2022
OMass Technologies Ltd engages in drug discovery by applying mass spectrometry to the characterization of intact protein assemblies. The company offers biotherapeutics, membrane proteins, drug binding, and purifications guiding services. In addition, OMass Technologies Ltd offers structural mass spectrometry (MS) platforms, often referred to as native mass spectrometry, for characterizing complex protein assemblies. The company assists biotechnology and pharmaceutical companies in tackling drug targets and biotherapeutics. OMass Technologies Ltd was founded in 2016 and is based in Begbroke, United Kingdom.

Obsidian Security

Series C in 2022
Obsidian Security, Inc. is a technology company based in Newport Beach, California, specializing in cybersecurity solutions tailored for hybrid-cloud environments. Founded in 2017 by former members of renowned companies in the security sector, Obsidian Security focuses on leveraging artificial intelligence to address cyber threats. Its platform provides comprehensive services, including threat detection, breach remediation, and security hardening specifically for software as a service (SaaS) applications. The company's offerings aim to deliver intelligent identity protection and seamless security, enabling enterprises to safeguard their interconnected systems without hindering productivity. Backed by notable investors, Obsidian Security positions itself at the forefront of the evolving cybersecurity landscape.

Brightline

Series C in 2022
Brightline is a technology-enabled behavioral health home for children and their families. Brightline delivers integrated care through innovative technology, virtual behavioral health services, and a collaborative care team focused on supporting children across developmental stages and their families.

Digits

Series C in 2022
Digits Financial, Inc. develops software to provide real-time view into business’ finance. The company’s software facilitates processes related to financial reports and transaction records to eliminate manual work. It visualizes, understands, and manages business and handles interactions with accountants, investors, and advisors. The company was founded in 2018 and is based in San Francisco, California.

Celsius Therapeutics

Series B in 2022
Celsius Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on the development and research of innovative drugs. Established in 2017, the company utilizes single-cell genomic analysis and machine learning to gain insights into the cellular ecosystems of diseases. This approach allows Celsius Therapeutics to identify critical biomarkers that can enhance patient care and contribute to the creation of transformative medicines. The company's commitment to advancing the understanding of complex diseases positions it as a key player in the biotechnology sector.

LifeMine Therapeutics

Series C in 2022
LifeMine Therapeutics, Inc., a biotechnology company, engages in the genomic discovery of new drug modalities from eukaryotic microbes. It utilizes an integrated genomically-enabled drug discovery platform to discover and develop a pipeline of new drugs from fungi. The company was incorporated in 2016 and is based in Cambridge, Massachusetts with an additional office in New York, New York.

Spotlight Therapeutics

Series B in 2022
Spotlight Therapeutics is a developer of gene editing therapeutics intended to edit specific cell populations directly in the body. The company's therapeutics are used to create next-generation programmable nucleases that can selectively target and edit cells, enabling physicians to treat their patient in an enhanced way.

Nothing

Series B in 2022
Nothing is removing the barriers between people and technology to create a seamless digital future.

Redpanda

Series B in 2022
Social Media Marketing Platform.

Redpanda Data

Series B in 2022
Redpanda is a queue for people who deal with massive data streams.

RightHand Robotics

Series C in 2022
RightHand Robotics, Inc. specializes in manufacturing robotic order-picking systems designed for various industrial applications, including e-commerce, food handling, and flexible manufacturing. The company offers innovative products such as the ReFlex SF, which features a 3D-printed palm equipped with servos and compliant fingers, and the ReFlex TakkTile, a tactile sensor that enhances the robots' ability to grasp items gently and make adjustments to avoid errors. Their technology allows robots to automatically grasp a wide range of items from bins and cases, eliminating the need for extensive data-entry or parameter-tuning, thereby making the systems cost-effective and adaptable to the evolving needs of businesses. Founded in 2015, RightHand Robotics is headquartered in Cambridge, Massachusetts, with a sales and business development office located in Frankfurt, Germany.

Genesis Global

Series C in 2022
GENESIS Global was originally started by a team of industry leaders in the Global Financial Markets space with extensive experience in front to back trading technologies across multiple asset classes and business lines. The members of their management and advisory team have held senior global management roles at investment banks around the world and at trading technology software vendors. Extensive experience with global financial technology vendors. They have a simple strategy, to be a global FinTech company providing best in class solutions and services which are in line with their client’s needs, goals and expectations. They have a disruptive framework technology and business model to achieve this strategy.

Homebound

Series C in 2022
Homebound Inc. is a technology-driven custom home builder based in Santa Rosa, California, founded in 2017. The company specializes in constructing residential homes and offers a comprehensive range of support services, including architecture, design, financing, and insurance consultancy. Originating in response to the 2017 Northern California wildfires, Homebound aims to simplify the homebuilding process by providing a transparent and streamlined experience for homeowners. It manages the entire building journey, assisting clients from insurance negotiation and architectural design to permitting and construction. By leveraging user-friendly technology and a network of qualified building professionals, Homebound addresses the complexities and uncertainties homeowners face, particularly in the aftermath of natural disasters, enabling them to rebuild their homes more efficiently.

Ventus Therapeutics

Series C in 2022
Ventus Therapeutics U.S., Inc. is a biopharmaceutical company based in Natick, Massachusetts, with an additional location in Montreal, Canada. Founded in 2019, it focuses on discovering and developing novel small-molecule medicines that target the innate immune system to address autoimmune diseases, inflammatory diseases, and cancer. The company employs a structural immunology platform that integrates protein engineering to elucidate molecular structures and mechanisms of action. This platform facilitates the development of precise binding and functional screening assays, as well as structure-based modeling. Ventus Therapeutics is advancing an emerging pipeline of drug programs aimed at key targets within the innate immune system, leveraging its proprietary capabilities in rational and structure-based drug design.

Pecan

Series C in 2022
Pecan is an AI-based predictive analytics platform that streamlines the creation and deployment of predictive models for various business applications, including customer lifetime value, churn prediction, and market segmentation. Founded in 2016 and headquartered in Tel Aviv, Israel, Pecan eliminates the need for data preparation or engineering by directly connecting to raw data. The platform features a low-code interface and pre-built models that automate the predictive process, allowing organizations to generate and implement AI models within days, without requiring data science expertise. This comprehensive approach enables businesses to make informed decisions by predicting future outcomes and identifying actionable insights efficiently.

Censys

Series B in 2022
Censys, Inc. is a cybersecurity company specializing in internet scanning and asset identification solutions. Founded in 2017 and based in Ann Arbor, Michigan, Censys provides an internet device search engine that allows users to discover and analyze devices connected to the Internet, including computers, servers, and smart devices. The platform is utilized for various applications such as attack surface management, monitoring remote workforces, and identifying potential threats. Censys is recognized for delivering real-time visibility and risk assessments, making it a valuable resource for researchers, corporations, and government entities. The company's data-driven security solutions are employed by notable organizations, including FireEye, Google, NATO, and the U.S. Department of Homeland Security, to enhance their cybersecurity measures and proactively address threats.

Leyden Labs

Series B in 2022
Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

Found

Series B in 2021
Found is dedicated to improving people’s overall wellbeing by making evidence based weight loss accessible & affordable for all.

Synthesia

Series B in 2021
Synthesia Ltd. develops artificial intelligence driven video production platform to create high-end videos. The company’s video synthesis platform allows to create high-end videos for many applications, including personalized advertising, corporate communications, and e-learning. Its platform synchronizes the lip movements in a video to a new dialogue track, which enables video content to be translated into foreign languages, widening distribution channels. The company was incorporated in 2017 and is based in London, United Kingdom.

Universe

Series B in 2021
Universe is a mobile-based website builder established in 2014 and headquartered in Brooklyn, New York. The platform aims to empower users to create customized websites quickly and easily, catering to the needs of small business owners and individuals who prefer mobile solutions. By offering a unique approach that eliminates complicated templates, Universe utilizes customizable website filters that allow users to arrange photos, videos, and icons on a grid pattern through a simple drag-and-drop interface. This enables users to build mobile-optimized websites in just minutes using the company's iOS app, providing them with full control over their online presence.

Upbound

Series B in 2021
Upbound, Inc. develops and offers a multi-cloud platform that enables organizations to treat multiple disparate cloud environments as one. The company's platform allows organizations to build scalable multi-cloud services. Its platform allows for automation, cost optimization, capacity overflow, failover, policy enforcement, and portability across cloud environments. The company was founded in 2017 and is based in Seattle, Washington.

mabl

Series C in 2021
Mabl Inc. offers an automated testing service that leverages machine learning to identify regressions and automatically fix broken tests. Founded in 2016 and based in Boston, Massachusetts, the company provides a scriptless testing solution as part of its software-as-a-service (SaaS) offerings. Mabl facilitates machine-driven regression testing and integrates seamlessly into the continuous integration and continuous delivery (CI/CD) development lifecycle. Its platform allows software development teams to create, execute, and maintain auto-healing tests efficiently, ensuring the rapid delivery of high-quality applications. Mabl serves a range of enterprise clients, including Johnson Controls, Liberty Mutual, Molina Healthcare, JetBlue, Dollar Shave Club, and Charles Schwab, who rely on its services for testing their critical applications.

Yellowbrick Data

Series C in 2021
Yellowbrick Data was founded in 2014 by experts in database and flash memory technologies to simplify data warehousing. They wanted to solve the challenges of high availability, running complex mixed workloads, support for ad-hoc SQL, computing correct answers on any schema, massive scalability and supporting large numbers of concurrent users. Yellowbrick Data empowers companies to make faster decisions with all of their data. Built for enterprises and the hybrid cloud, the Yellowbrick Data Warehouse deploys powerful analytics anywhere, with best-in-class economics.

Multiverse

Series C in 2021
Multiverse offers apprenticeship opportunities tailored for non-graduate individuals, positioning itself as an alternative to traditional university education. Founded in 2016 and based in London, the company focuses on providing career-oriented apprenticeships that empower young people to take charge of their professional journeys. By facilitating access to high-quality training and resources, Multiverse aims to create a fulfilling career path for its participants, moving away from conventional corporate training methods. The company also incorporates digital tools to help apprentices build their profiles and engage in social networking, enhancing their learning experience and career prospects.

StrongDM

Series B in 2021
strongDM manages and audits access to servers and databases. It provides a single platform to control access to any database for employees, vendors, and cloud-based tools. The company was awarded in the Strata+Hadoop World Audience Favorite in 2016. It was incorporated in 2015 and is headquartered in Burlingame, California.

ROME Therapeutics

Series B in 2021
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, ROME Therapeutics is pioneering the exploration of the repeatome, which consists of extensive regions of genetic material previously considered "junk DNA." The company has identified several drug targets and is actively advancing multiple discovery programs. To facilitate its research, ROME has assembled a team of experts across various disciplines, including oncology, immunology, virology, and machine learning, to harness this uncharted area of biology for therapeutic advancements.

Genome Medical

Series C in 2021
Genome Medical, Inc. is a national telegenomics company that specializes in providing genetic consultation and medical consulting services. Incorporated in 2016 and based in South San Francisco, California, the company utilizes its Genome Care Delivery technology platform to deliver genetic solutions across various clinical areas, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacy. By leveraging a nationwide network of genetic specialists, Genome Medical offers expert virtual genetic care to individuals and families, enhancing their health and well-being. The company also assists healthcare providers and patients in navigating the expanding field of genetics, enabling them to interpret test results, assess disease risk, expedite diagnoses, make informed treatment choices, and reduce healthcare costs.

Ultromics

Series B in 2021
They are building world-class diagnostic aids to help cardiologists — powered by artificial intelligence. To date, they have developed the world’s most accurate echocardiography software to improve the diagnosis of coronary heart disease by more than 90%.

Snorkel AI

Series C in 2021
Snorkel AI, Inc. is a technology company that specializes in developing an end-to-end machine-learning platform designed for building, managing, and monitoring AI applications. Central to its offerings is Snorkel Flow, a data-first platform that enables users to programmatically label and augment training data, manage and integrate data for AI purposes, and train and deploy various models. The platform also facilitates the extraction of entities and relationships from complex documents and ranks content based on relevance. This technology is beneficial across multiple sectors, including finance, government, telecommunications, insurance, healthcare, and e-commerce. Founded in 2016 and based in Palo Alto, California, Snorkel AI is committed to making AI practical through its innovative tools and solutions.

Neuralink

Series C in 2021
Neuralink Corp. is a neural technology company focused on developing brain-computer interfaces (BCIs) that facilitate direct communication between the human brain and computers. Founded in 2016 and headquartered in San Francisco, California, with an additional office in Burlingame, the company aims to create implants that can treat brain injuries and trauma. Neuralink's innovative approach includes a concept referred to as a "neural lace," which would be surgically integrated into the brain, enabling users to interact with computers without the limitations of traditional input methods like keyboards and mice. The company is also exploring the potential of brain interfaces to alleviate symptoms of serious and chronic medical conditions, striving to enhance cognitive capabilities and keep pace with advances in artificial intelligence.

TMRW Life Sciences

Series C in 2021
TMRW Life Sciences is a developer of a cryo-storage platform intended to improve the success rates of assisted reproductive technology. The company's platform offers an in-clinic robotic storage system and a fully digital chain of custody from clinic to offsite longterm storage, continuous remote and local monitoring and electronically integrated processes characterized by digital health signals received from every oocyte and embryo daily, enabling clients to streamline embryology lab operations, eliminate manual steps and integrates digital quality control.

Resolution Games

Series C in 2021
Resolution Games AB is a gaming studio based in Stockholm, Sweden, founded in 2015. The company specializes in developing virtual reality (VR) and augmented reality (AR) games, aiming to create immersive experiences for players. With a team of industry experts, Resolution Games focuses on producing a diverse catalog of titles that enhance the sense of presence and engagement through cutting-edge technology. The studio's games are designed to be available across multiple platforms, catering to a wide audience of gaming enthusiasts.

Instawork

Series C in 2021
Instawork is the fastest growing career marketplace for hospitality professionals. We've changed how traditional recruiting works for small businesses (e.g a sign on the window) by turning the process into an automated matching solution. Our vision is to create economic opportunity for local businesses and professionals, globally. We're rapidly expanding across the US. We're looking for great talent to help us grow and would love to hear from you! Go to www.instawork.com or send us a note at careers@instawork.com

Physna

Series B in 2021
Physna LLC designs and develops geometric search engine software for computer-aided design, 3-Diemsional printing, and other manufacturing methods. Its search engine breaks down 3-D files into a codified structure; and allows users to compare and analyze 3D models for the purpose of quality control and automated inspection. The company serves design, manufacturing, cybersecurity, aerospace, automotive, defense, consumer goods, electronics, and energy industries. Physna LLC was founded in 2015 and is based in Cincinnati, Ohio.

Kindbody

Series C in 2021
Kindbody operates a health and tech company intended to offer fertility services and treatments for the modern woman. It offers a full range of services including intrauterine insemination, in-vitro fertilization, donor support, egg freezing, and embryo freezing, enabling women to improve their overall health and wellbeing.

Vercel

Series C in 2021
Vercel is a video production company that produces high quality video content for brands like Netflix, Amgen, Willis Towers Watson and UCLA. We have produces videos for a wide array of applications including TV commercials, for websites, trainings, social media, trade shows and sales meetings.

Sense

Series C in 2021
Sense is an automated communication and engagement platform specifically designed for enterprise recruiting teams and the staffing industry. The platform aims to enhance talent engagement by providing tools that help reduce turnover and increase re-deployment rates. It offers a real-time, comprehensive view of consultants, enabling organizations to better understand their workforce dynamics. Based in San Francisco, Sense has attracted investment from notable venture capital firms, including Accel, GV, Khosla Ventures, Signia Ventures, and IDG SF.

Brightline

Series B in 2021
Brightline is a technology-enabled behavioral health home for children and their families. Brightline delivers integrated care through innovative technology, virtual behavioral health services, and a collaborative care team focused on supporting children across developmental stages and their families.

The Pill Club

Series B in 2021
The Pill Club is a healthcare service that specializes in delivering birth control and related products across the United States. Founded in 2014 and based in California, it operates as an online retailer and pharmacy, providing a convenient way for women to access birth control, emergency contraceptives, and wellness gifts. The Pill Club is supported by a team of medical professionals and aims to empower women by facilitating personalized healthcare experiences. It offers prescription services in 34 states and Washington D.C., ensuring widespread access to its products. With a focus on women's health and well-being, the company strives to enhance personal freedom and health ownership through its innovative telemedicine approach.

Ribon Therapeutics

Series C in 2021
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.

PostHog

Series B in 2021
PostHog is increasing the number of successful products in the world. We do that by providing a platform for open-source product analytics. This helps software teams understand user behaviour. We took part in Y Combinator’s W20 cohort, and had the most successful B2B software launch on HackerNews since 2012, with a product that was just 4 weeks old. Our team is a combination of former CTOs and YC founders all turned developers, alongside some of the best developers from the world's largest tech companies who have the experience to help us handle scalability. We're all remote, and we've raised enough to pay top of market. We are proudly backed by some of the best VCs and Investors in the world, such as Y Combinator. We believe in product-led growth, while we build something awesome and let our product bring the users, rather than an outbound sales team and regular cold calls. Check out posthog.com/careers if you want to be part of this journey.

Lovevery

Series C in 2021
Lovevery, Inc. is a company based in Boise, Idaho, that specializes in manufacturing educational play products for infants. Founded in 2015, Lovevery offers a range of items designed to support early childhood development, including the Play Gym, which features various toys and tools that engage babies' senses and promote learning at different developmental stages. The company's products are informed by child development experts and aim to provide parents with stage-based information to enhance their children's growth. Lovevery sells its offerings primarily online and has received recognition for its innovative designs from several notable organizations, including TIME Magazine and Parents' Choice. The company is backed by prominent investors such as Maveron and the Chan Zuckerberg Initiative.

Clear Labs

Series C in 2021
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company offers a comprehensive food analytics platform that utilizes next-generation sequencing to analyze the molecular contents of foods and ingredients. This platform provides food manufacturers, suppliers, and retailers with crucial transparency across supply chains, testing products for authenticity, contaminants, allergens, and various other factors such as GMOs, heavy metals, and nutrition. Clear Labs also focuses on simplifying complex diagnostics for clinical and applied markets, combining DNA sequencing, robotics, and cloud-based analytics to improve accuracy and accelerate outcomes. By delivering insights into food safety and quality, Clear Labs aims to enhance understanding and management of potential health risks associated with food products and emerging pathogens.

Merlin Labs

Series B in 2021
Merlin Labs is building an autonomous infrastructure for the sky above us, enabling goods, and eventually people, to fly without pilots.

Bowery Farming

Series C in 2021
Bowery Farming Inc., a farming company, provides post-organic produce. The company offers baby kale, blend, lettuce, arugula, kale mix, and basil products. It sells its products through grocery stores and restaurants. The company was founded in 2014 and is based in New York, New York.

Overture Life

Series B in 2021
Overture Life, Inc. develops robots for in vitro fertilization applications. The company was incorporated in 2017 and is based in New York, New York.

oneNav

Series B in 2021
OneNav provides a mobile positioning system intended for smartphones, wearables, and IoT tracking devices. The system utilizes the modernized L5 signaling band from navigation satellite constellations which enable clients to get upgraded data-rich signals with accurate and reliable tracking applications. Stephen Poizner and Paul McBurney co-founded oneNav in Palo Alto, California in 2019.

Smol

Series B in 2021
smol Limited manufactures detergents and laundry capsules. The company also manufactures fabric conditioner. It sells its products online. The company was incorporated in 2017 and is based in Crawley, United Kingdom.

Headway

Series B in 2021
Headway is a mental healthcare system provider based in New York, established in 2019 by founders Andrew Adams, Jake Sussman, Dan Ross, and Kevin Chan. The company focuses on improving access to mental health services by developing a health insurance advisory platform that connects patients with therapists who traditionally do not accept insurance. In addition to facilitating these connections, Headway offers administrative support to therapists, enhancing their ability to provide care while navigating the complexities of insurance processes. Through this approach, Headway aims to make mental healthcare more accessible and efficient for both patients and providers.

Affinia Therapeutics

Series B in 2021
Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for various diseases, particularly those affecting muscle and the central nervous system (CNS). Founded in 2019 and based in Waltham, Massachusetts, the company specializes in creating rationally designed adeno-associated virus (AAV) vectors. By integrating synthetic and systems biology with high-throughput screening and advanced resolution techniques, Affinia Therapeutics aims to address significant unmet medical needs. The company’s innovative approach allows for the development of novel gene therapies with enhanced properties, targeting the treatment of devastating diseases and improving the lives of affected individuals.

Outlier

Series B in 2021
Outlier.org Inc. develops an online educational platform. It offers Outlier.org, a platform that provides online courses on calculus and psychology. The company’s platform also provides video content, online textbooks, one-on-one tutoring, artificial intelligence-proctored assessments, problem sets, and active learning techniques. Outlier.org Inc. was formerly known as Outlier School Inc. The company was incorporated in 2018 and is based in Brooklyn, New York.

Invivyd

Series C in 2021
Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.

Tend

Series C in 2021
Tend provides hassle-free, personalized, and straightforward dental services with a focus on patient happiness. Tend studios offer a full range of dental services, from checkups to implants and veneers. Tend prioritizes safety with health checks, contactless check-in, enhanced PPE, and more.

Ventus Therapeutics

Series B in 2021
Ventus Therapeutics U.S., Inc. is a biopharmaceutical company based in Natick, Massachusetts, with an additional location in Montreal, Canada. Founded in 2019, it focuses on discovering and developing novel small-molecule medicines that target the innate immune system to address autoimmune diseases, inflammatory diseases, and cancer. The company employs a structural immunology platform that integrates protein engineering to elucidate molecular structures and mechanisms of action. This platform facilitates the development of precise binding and functional screening assays, as well as structure-based modeling. Ventus Therapeutics is advancing an emerging pipeline of drug programs aimed at key targets within the innate immune system, leveraging its proprietary capabilities in rational and structure-based drug design.

Snorkel AI

Series B in 2021
Snorkel AI, Inc. is a technology company that specializes in developing an end-to-end machine-learning platform designed for building, managing, and monitoring AI applications. Central to its offerings is Snorkel Flow, a data-first platform that enables users to programmatically label and augment training data, manage and integrate data for AI purposes, and train and deploy various models. The platform also facilitates the extraction of entities and relationships from complex documents and ranks content based on relevance. This technology is beneficial across multiple sectors, including finance, government, telecommunications, insurance, healthcare, and e-commerce. Founded in 2016 and based in Palo Alto, California, Snorkel AI is committed to making AI practical through its innovative tools and solutions.

Lightmatter

Series B in 2021
Lightmatter, Inc. is an artificial intelligence (AI) hardware company based in Boston, Massachusetts, that specializes in integrated optical technology to develop advanced computing processors. Founded in 2017, the company has created a silicon chip that utilizes light signals for processing, offering a new approach to AI computation. This technology accelerates critical operations in deep neural networks by employing programmable photonic elements alongside traditional transistors, enhancing the speed and efficiency of data processing while minimizing power consumption. Lightmatter's innovations aim to improve various AI applications, including image recognition and natural language processing, contributing to the advancement of next-generation AI-powered computing solutions.

Insitro

Series C in 2021
Insitro is a operator of a data-driven drug discovery and development company that uses machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company uses state-of-the-art technologies from Bioengineering enabling it to generate high-throughput, functional genomic data sets and aligning them with patient data via a novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.

Genesis Global

Series B in 2021
GENESIS Global was originally started by a team of industry leaders in the Global Financial Markets space with extensive experience in front to back trading technologies across multiple asset classes and business lines. The members of their management and advisory team have held senior global management roles at investment banks around the world and at trading technology software vendors. Extensive experience with global financial technology vendors. They have a simple strategy, to be a global FinTech company providing best in class solutions and services which are in line with their client’s needs, goals and expectations. They have a disruptive framework technology and business model to achieve this strategy.

Monte Rosa Therapeutics

Series C in 2021
Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.

Tenaya Therapeutics

Series C in 2021
Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts ; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was founded in 2016 and is headquartered in South San Francisco, California.

Nanit

Series C in 2021
Nanit team is a tight-knit collection of scientists, parents and designers—experts in the first beautiful months of human life. They have developed advanced computer vision and machine learning algorithms to help us measure human behavior. They use this knowledge and technology to create innovative products that are safer and smarter, for parents and babies everywhere. Their team comes from great companies like Applied Materials, Diapers.com, Philips, Time Warner and Tiny Love, where they've focused on building brands and products people love.

Evox Therapeutics

Series C in 2021
Evox Therapeutics Limited develops a modular platform for clinical translation of exosome-based therapeutics. The company develops extracellular vesicles-based nucleic acid and protein delivery technology. Its technology aims to hitch a ride on tiny particles called exosomes, which the body uses to transport molecules between cells. Evox Therapeutics Limited was founded in 2016 and is based in Oxford, United Kingdom.

Dandelion Energy

Series B in 2021
Dandelion Energy offers affordable geothermal heating and cooling installations. Dandelion Energy's home geothermal system replaces your home’s existing air conditioning and heating equipment with a powerful heat pump and safe, underground pipes that move heat between the earth and home. Kathleen Hannun and Rajeez Quazi founded it in 2017, with its headquarters in Palo Alto in California.

TScan Therapeutics

Series C in 2021
TScan Therapeutics is a biopharmaceutical company dedicated to developing innovative T cell therapies to treat various cancers, including liquid tumors and solid tumors. The company focuses on engineering T cell receptor (TCR) therapies, with specific candidates aimed at addressing hematologic malignancies and preventing relapse after hematopoietic stem cell transplantation. TScan utilizes a specialized platform that identifies shared T cell antigens and minimizes off-target effects, enhancing the safety and effectiveness of its treatments. The company’s pipeline includes both liquid tumor therapies and multiplexed TCR-T candidates for solid tumors. Founded in 2018, TScan Therapeutics is headquartered in Waltham, Massachusetts, and comprises a team of experts committed to expanding treatment options for patients with limited therapeutic alternatives.

Vera Therapeutics

Series C in 2021
Trucode Gene Repair, Inc. operates a triplex gene editing platform for curing genetic diseases. It focuses on sickle cell disease and cystic fibrosis. The company develops a pipeline of novel, proprietary therapeutic products for high-penetrance disease genes to alleviate and cure genetic disorders in patients. The company was founded in 2016 and is based in South San Francisco, California.

Verve Therapeutics

Series B in 2021
Verve Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to reduce the risk of coronary artery disease, a leading cause of death globally. Founded in 2018 and headquartered in Cambridge, Massachusetts, with a research facility in Philadelphia, the company leverages human genetic analysis and gene-editing technologies to create treatments that offer lifelong protection from this condition. Verve has established strategic alliances, including collaborations with Beam Therapeutics to advance delivery technologies targeting cardiovascular issues and with Verily for developing gene editing delivery vehicles. Formerly known as Endcadia, Verve Therapeutics rebranded in September 2019 to reflect its commitment to addressing heart disease through advanced genetic solutions.

Multiverse

Series B in 2021
Multiverse offers apprenticeship opportunities tailored for non-graduate individuals, positioning itself as an alternative to traditional university education. Founded in 2016 and based in London, the company focuses on providing career-oriented apprenticeships that empower young people to take charge of their professional journeys. By facilitating access to high-quality training and resources, Multiverse aims to create a fulfilling career path for its participants, moving away from conventional corporate training methods. The company also incorporates digital tools to help apprentices build their profiles and engage in social networking, enhancing their learning experience and career prospects.

EQRx

Series B in 2021
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.

LifeMine Therapeutics

Series B in 2021
LifeMine Therapeutics, Inc., a biotechnology company, engages in the genomic discovery of new drug modalities from eukaryotic microbes. It utilizes an integrated genomically-enabled drug discovery platform to discover and develop a pipeline of new drugs from fungi. The company was incorporated in 2016 and is based in Cambridge, Massachusetts with an additional office in New York, New York.

FogPharma

Venture Round in 2021
FogPharma is a healthcare company founded in 2015 and headquartered in Gloucester, Massachusetts. The firm is dedicated to the pharmaceutical sector, with a primary focus on developing innovative treatments for cancer. It operates with the support of a diverse group of private and institutional investors, fostering collaboration among its founders, employees, and advisors. FogPharma aims to create a new class of medicines designed to extend and enhance the lives of cancer patients. The company's commitment to its mission drives its efforts to pioneer effective solutions in cancer treatment.

AMP Robotics

Series B in 2021
AMP Robotics Corporation specializes in designing and manufacturing robotic systems for material recovery facilities and recycling operations, focusing on automating the identification, sorting, and processing of complex waste streams. The company's flagship product, AMP Cortex, utilizes advanced robotics and computer vision technology to efficiently pick and sort recyclable materials, significantly lowering sorting costs. Additionally, AMP Neuron, a software solution, captures and analyzes material data to identify features in a manner similar to human perception. By leveraging artificial intelligence and machine learning, AMP Robotics enhances recycling processes for various waste types, including municipal solid waste and e-waste. The modular design of its systems allows for easy integration into existing infrastructure, minimizing disruption and capital investment. Founded in 2014 and headquartered in Louisville, Colorado, AMP Robotics has formed strategic partnerships to further its mission of improving recycling rates and economic recovery of recyclables.

Encodia

Series C in 2020
Encodia, Inc. engages in proteomics research and creates scalable and parallelized approaches to protein analysis. The company was founded in 2015 and is based in San Diego, California.

Vercel

Series B in 2020
Vercel is a video production company that produces high quality video content for brands like Netflix, Amgen, Willis Towers Watson and UCLA. We have produces videos for a wide array of applications including TV commercials, for websites, trainings, social media, trade shows and sales meetings.

Locanabio

Series B in 2020
Locanabio, Inc., is an RNA-targeting gene therapy company focused on developing therapies for patients with severe neurodegenerative, neuromuscular, and retinal diseases.

Hodinkee

Series B in 2020
Established in 2008, HODINKEE is the destination for all things in the world of horology. Over the past decade, ​founder Ben Clymer and team have​ grown HODINKEE into a robust media and retail platform by providing its respected point of view on industry news and releases, investing in engaging and creative storytelling, producing a designated podcast, printing a bi-annual publication, and launching and growing its own retail outlet, HODINKEE Shop. At its core, HODINKEE’s goal is to bring its readers and consumers the best in luxury products in a way that is approachable, authentic, and honest.

Flock Freight

Series C in 2020
Flock Freight Inc. specializes in less-than-truckload (LTL) freight shipping and management services across North America. The company uses innovative algorithms to pool LTL and partial-truckload shipments into full truckloads, enhancing efficiency and reducing costs for businesses. Its flagship product, FlockDirect, enables seamless transportation of pooled freight without the need for terminals, ensuring safe and direct deliveries. Additionally, Flock Freight offers a technology platform that consolidates multiple shipments into multi-stop routes, optimizing logistics for shippers and maximizing revenue opportunities for carriers. Founded in 2015 and headquartered in Solana Beach, California, Flock Freight aims to transform the LTL freight industry through advanced technology and a focus on customer experience.

Resilience

Series B in 2020
Resilience, formally known as National Resilience, Inc., is a biopharmaceutical manufacturing and technology company established in 2020 and headquartered in La Jolla, California. The company specializes in end-to-end manufacturing and development solutions, focusing on advanced manufacturing technologies for various therapeutic modalities, including cell and gene therapies, viral vectors, vaccines, and proteins. Resilience is committed to expanding access to complex medicines and ensuring the stability of biopharmaceutical supply chains against potential disruptions. Through its innovative approaches, the company aims to enhance the efficiency and security of biopharmaceutical production, ultimately contributing to improved healthcare outcomes.

Invivyd

Series B in 2020
Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.

Weaveworks

Venture Round in 2020
Weaveworks Limited, founded in 2014 and headquartered in London with an office in San Francisco, is a software company that specializes in open-source solutions for managing cloud-native applications. The company develops tools that simplify the operation of Kubernetes workloads, allowing developers and DevOps teams to build and manage containerized applications efficiently. Its key products include Weave Net, a software-defined networking solution for Docker containers; Weave Scope, which provides real-time visibility and interaction with distributed applications; and Weave Flux, which automates the management of microservices. Additionally, Weaveworks offers Weave Cloud, a Software-as-a-Service platform that facilitates the connection, monitoring, and deployment of containers. The company is recognized for its contributions to the Cloud Native Computing Foundation and various open-source projects, enhancing the developer experience in the cloud-native ecosystem.

Superplastic

Series B in 2020
Superplastic, Inc. is a character-based product and entertainment company founded in 2017 and based in Burlington, Vermont. The company specializes in manufacturing and marketing limited edition art toys, apparel, games, and animation, featuring unique characters created in collaboration with renowned artists. Superplastic leverages the principles of effort and scarcity to enhance the value of its offerings, creating exclusive works of art for a select audience. The company also operates a platform that engages customers through various media, including animated videos and music, enabling interactions with its synthetic superstars in innovative ways. Products are primarily sold online, reflecting a modern approach to retail and entertainment.

Alkira

Series B in 2020
Alkira, Inc. is a provider of a network cloud platform that enables businesses to establish multi-cloud network connectivity quickly and efficiently. Founded in 2018 and headquartered in San Jose, California, Alkira offers a pay-as-you-go service that allows customers to connect their local systems and cloud workloads to its Cloud Exchange Points (CXP). The platform supports on-demand activation of security and other services, which can automatically scale based on usage. Alkira's Network Cloud integrates network and security services, provides comprehensive operational visibility, and features advanced controls for governance. Users can easily design their network across various users, sites, and clouds using an intuitive digital canvas, enabling rapid provisioning and deployment. Alkira's solutions are utilized by Fortune 100 companies, prominent system integrators, and managed service providers, marking its significant presence in the network-as-a-service sector.

Tend

Series B in 2020
Tend provides hassle-free, personalized, and straightforward dental services with a focus on patient happiness. Tend studios offer a full range of dental services, from checkups to implants and veneers. Tend prioritizes safety with health checks, contactless check-in, enhanced PPE, and more.

Monte Rosa Therapeutics

Series B in 2020
Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.